BU
MYGN icon

BBVA USA’s Myriad Genetics MYGN Stock Holding History

BBVA USA’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2K Sell
71
-229
-76% -$7.61K ﹤0.01% 930
2021
Q2 		$9K Buy
+300
New +$8.67K ﹤0.01% 872

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

BBVA USA's MYGN Position: Q3 2021 in Review

BBVA USA reduced its Myriad Genetics (MYGN) stake by 76% in Q3 2021, selling an estimated $7.61K and leaving 71 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #930.

BBVA USA first reported a position in MYGN in Q2 2021 and has held it in 2 quarters since. The position peaked at $9K in Q2 2021. 213 funds tracked by Wall St. Rank hold MYGN as of Q3 2021.

  • BBVA USA held 71 shares of Myriad Genetics worth $2K as of Q3 2021.
  • BBVA USA sold 229 Myriad Genetics shares in Q3 2021, an estimated $7.61K.
  • Myriad Genetics made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #930 holding.
  • BBVA USA first reported a position in Myriad Genetics in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Myriad Genetics position peaked at $9K in Q2 2021.
  • 213 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.